Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,043.47 +292.29 (+0.46%) CMC Crypto 200
1,331.07 +54.09 (+4.23%)
SWTX Sep 2024 50.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:04AM EDT. Market open.
| Previous close | 4.4500 |
| Open | 4.4600 |
| Bid | 3.4000 |
| Ask | 6.6000 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 4.4500 - 4.4600 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
Simply Wall St.Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
GlobeNewswireSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc
© 2024 Yahoo. All rights reserved.